Related Experiment Video
Updated: Mar 22, 2026
11:20
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
4.5K
Transient Subfoveal Fluid and Visual Loss after Ocriplasmin.
1Augenzentrum Klinik Pallas, Olten, Switzerland (Director: Prof. Dr. Heinrich Gerding).
Klinische Monatsblatter Fur Augenheilkunde
|April 27, 2016
Summary
Intravitreal ocriplasmin injection resolved vitreomacular traction in 5 of 12 patients. However, 9 patients developed subfoveal fluid, impacting visual acuity, though it later resolved.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Ocriplasmin, an enzyme for vitreomacular traction, received EU approval in 2013.
- Clinical findings and adverse effects beyond the registration trial are reported.
Purpose of the Study:
- To report clinical findings and adverse effects of ocriplasmin in treating vitreomacular traction.
- To investigate subfoveal fluid development and its impact on visual acuity.
Main Methods:
- Retrospective analysis of 12 consecutive patients treated with intravitreal ocriplasmin.
- Monitoring of vitreomacular traction resolution, subfoveal fluid, and visual acuity post-injection.
Main Results:
- Vitreomacular traction resolved in 5 of 12 patients.
- Subfoveal fluid developed in 9 patients, causing a significant visual acuity reduction.
- Subfoveal fluid resolved in most cases within 6 weeks, with visual acuity returning to baseline.
Conclusions:
- The high incidence of subfoveal fluid post-ocriplasmin injection was unexpected.
- Potential causes include enzymatic disruption of photoreceptor-RPE interactions or RPE barrier dysfunction.
- Further investigation into ocriplasmin's mechanism and safety profile is warranted.
Related Concept Videos
01:25Glaucoma: Overview
1.6K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K
01:28Angle Closure Glaucoma: Treatment
1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K